NASDAQ:PRPH - ProPhase Labs Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 67.66 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$8.35
▲ +0.17 (2.08%)

This chart shows the closing price for PRPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProPhase Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRPH

Analyst Price Target is $14.00
▲ +67.66% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ProPhase Labs in the last 3 months. The average price target is $14.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 67.66% upside from the last price of $8.35.

This chart shows the closing price for PRPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in ProPhase Labs. This rating has held steady since November 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2022HC WainwrightLower Price TargetBuy$16.00 ➝ $14.00Medium
3/31/2022HC WainwrightBoost Price TargetBuy$15.00 ➝ $16.00Medium
1/14/2022HC WainwrightBoost Price TargetBuy$12.00 ➝ $15.00Low
12/20/2021HC WainwrightInitiated CoverageBuy$12.00High
10/13/2021Dawson JamesDowngradeBuy ➝ NeutralMedium
1/20/2021Dawson JamesInitiated CoverageBuy$25.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/27/2021
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/26/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/25/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2022
  • 7 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/25/2022

Current Sentiment

  • 7 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
ProPhase Labs logo
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Read More

Today's Range

Now: $8.35
Low: $8.23
High: $8.55

50 Day Range

MA: $7.43
Low: $6.52
High: $8.47

52 Week Range

Now: $8.35
Low: $4.44
High: $8.58

Volume

56,485 shs

Average Volume

26,488 shs

Market Capitalization

$129.31 million

P/E Ratio

8.27

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ProPhase Labs?

The following equities research analysts have issued research reports on ProPhase Labs in the last twelve months: Dawson James, HC Wainwright, StockNews.com, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for PRPH.

What is the current price target for ProPhase Labs?

0 Wall Street analysts have set twelve-month price targets for ProPhase Labs in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 67.7%.
View the latest price targets for PRPH.

What is the current consensus analyst rating for ProPhase Labs?

ProPhase Labs currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRPH will outperform the market and that investors should add to their positions of ProPhase Labs.
View the latest ratings for PRPH.

How do I contact ProPhase Labs' investor relations team?

ProPhase Labs' physical mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company's listed phone number is (215) 345-0919 and its investor relations email address is [email protected] The official website for ProPhase Labs is www.prophaselabs.com. Learn More about contacing ProPhase Labs investor relations.